Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Pliant Therapeutics stock

Own Pliant Therapeutics stock in just a few minutes.

Pliant Therapeutics, Inc is a biotechnology business based in the US. Pliant Therapeutics shares (PLRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pliant Therapeutics employs 78 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pliant Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PLRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Pliant Therapeutics share price

Use our graph to track the performance of PLRX stocks over time.

Pliant Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$19.43 - $43.92
50-day moving average $35.44
200-day moving average $29.21
Wall St. target price$51.50
PE ratio 42.7543
Dividend yield N/A (0%)
Earnings per share (TTM) $0.27

Buy Pliant Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pliant Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Pliant Therapeutics under- or over-valued?

Valuing Pliant Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pliant Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pliant Therapeutics's P/E ratio

Pliant Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 43x. In other words, Pliant Therapeutics shares trade at around 43x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Pliant Therapeutics's EBITDA

Pliant Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $20.8 million.

The EBITDA is a measure of a Pliant Therapeutics's overall financial performance and is widely used to measure a its profitability.

Pliant Therapeutics financials

Revenue TTM $41.8 million
Gross profit TTM $41.8 million
Return on assets TTM -12.56%
Return on equity TTM -21.13%
Profit margin -99.32%
Book value N/A
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Pliant Therapeutics shares

There are currently 1.8 million Pliant Therapeutics shares held short by investors – that's known as Pliant Therapeutics's "short interest". This figure is 25.7% up from 1.4 million last month.

There are a few different ways that this level of interest in shorting Pliant Therapeutics shares can be evaluated.

Pliant Therapeutics's "short interest ratio" (SIR)

Pliant Therapeutics's "short interest ratio" (SIR) is the quantity of Pliant Therapeutics shares currently shorted divided by the average quantity of Pliant Therapeutics shares traded daily (recently around 280485.87127159). Pliant Therapeutics's SIR currently stands at 6.37. In other words for every 100,000 Pliant Therapeutics shares traded daily on the market, roughly 6370 shares are currently held short.

However Pliant Therapeutics's short interest can also be evaluated against the total number of Pliant Therapeutics shares, or, against the total number of tradable Pliant Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Pliant Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Pliant Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0676% of the tradable shares (for every 100,000 tradable Pliant Therapeutics shares, roughly 68 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Pliant Therapeutics.

Find out more about how you can short Pliant Therapeutics stock.

Pliant Therapeutics share dividends

We're not expecting Pliant Therapeutics to pay a dividend over the next 12 months.

Pliant Therapeutics overview

Pliant Therapeutics, Inc. , a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in Phase II single ascending dose/multiple ascending dose trails and completed Phase Ib proof-of-mechanism trials for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was founded in 2015 and is based in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site